HK1072908A1 - Growth hormone releasing peptides - Google Patents

Growth hormone releasing peptides

Info

Publication number
HK1072908A1
HK1072908A1 HK05106694.1A HK05106694A HK1072908A1 HK 1072908 A1 HK1072908 A1 HK 1072908A1 HK 05106694 A HK05106694 A HK 05106694A HK 1072908 A1 HK1072908 A1 HK 1072908A1
Authority
HK
Hong Kong
Prior art keywords
growth hormone
hormone releasing
releasing peptides
peptides
growth
Prior art date
Application number
HK05106694.1A
Other languages
English (en)
Inventor
Zheng Xin Dong
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of HK1072908A1 publication Critical patent/HK1072908A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
HK05106694.1A 2002-08-09 2005-08-03 Growth hormone releasing peptides HK1072908A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40226302P 2002-08-09 2002-08-09
PCT/US2003/024834 WO2004014415A1 (fr) 2002-08-09 2003-08-08 Peptides liberant des hormones de croissance

Publications (1)

Publication Number Publication Date
HK1072908A1 true HK1072908A1 (en) 2005-09-16

Family

ID=31715820

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05106694.1A HK1072908A1 (en) 2002-08-09 2005-08-03 Growth hormone releasing peptides

Country Status (23)

Country Link
US (7) US7456253B2 (fr)
EP (2) EP2130548A3 (fr)
JP (2) JP4365319B2 (fr)
KR (1) KR100967572B1 (fr)
CN (3) CN1674927A (fr)
AR (2) AR040965A1 (fr)
AT (1) ATE447411T1 (fr)
AU (1) AU2003259062B2 (fr)
BR (2) BRPI0313273B8 (fr)
CA (1) CA2494300C (fr)
CZ (1) CZ20041254A3 (fr)
DE (1) DE60329923D1 (fr)
DK (1) DK1542716T3 (fr)
ES (1) ES2334223T3 (fr)
HK (1) HK1072908A1 (fr)
IL (1) IL165998A (fr)
MX (1) MXPA05000974A (fr)
NO (1) NO20050205L (fr)
PL (1) PL212138B1 (fr)
RU (2) RU2323941C2 (fr)
SG (1) SG177006A1 (fr)
TW (1) TWI331922B (fr)
WO (1) WO2004014415A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
EP1539959A2 (fr) * 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Analogues de ghrh
WO2004071448A2 (fr) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Derives d'azole substitues comme agents therapeutiques
WO2006045314A2 (fr) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Utilisation d'un secretagogue de l'hormone de croissance en vue d'accroitre ou de maintenir la masse maigre et/ou pour le traitement de la maladie pulmonaire obstructive chronique
EP1828243A2 (fr) * 2004-11-30 2007-09-05 Gastrotech Pharma A/S Ligands du recepteur 1a de secretagogue de l'hormone de croissance
JP4879265B2 (ja) * 2005-07-22 2012-02-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 成長ホルモン分泌促進薬
CN103251933A (zh) * 2005-09-29 2013-08-21 益普生制药股份有限公司 用于刺激胃肠运动性的组合物和方法
EP1818061A1 (fr) * 2005-12-02 2007-08-15 Charite-Universitätsmedizin Berlin Utilisation de la ghréline pour stimuler la pousse des cheveux
CU23592A1 (es) * 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
WO2007106385A2 (fr) 2006-03-10 2007-09-20 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Utilisation d'un agoniste de la ghréline pour améliorer les effets cataboliques d'un traitement aux glucocorticoïdes
WO2007127457A2 (fr) * 2006-04-28 2007-11-08 The Administrators Of The Tulane Educational Fund Antagonistes de récepteur de sécrétagogue d'hormone de croissance/de peptide libérant une hormone de croissance/de ghréline et utilisations de ceux-ci
RU2459831C2 (ru) * 2006-09-27 2012-08-27 Ипсен Фарма С.А.С. Аналоги грелина с замещением на n-конце
JP5247678B2 (ja) 2007-03-12 2013-07-24 雪印メグミルク株式会社 成長ホルモン分泌促進剤
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
WO2009108364A2 (fr) * 2008-02-27 2009-09-03 Ipsen Pharma S.A.S. Analogues antagonistes de ghrh
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
UA104945C2 (uk) * 2010-03-15 2014-03-25 Іпсен Фарма С.А.С. Фармацевтична композиція лігандів рецепторів секретагогів гормону росту
CN108929375A (zh) * 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
RU2625793C2 (ru) 2011-12-23 2017-07-19 Ипсен Мэньюфэкчеринг Айэлэнд Лимитед Способ синтеза терапевтических пептидов
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
EP2705835A1 (fr) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CN106459149A (zh) * 2014-03-04 2017-02-22 莫图斯治疗公司 H‑inp‑(d)bal‑(d)trp‑phe‑apc‑nh2及其可药用盐的液相合成的方法
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US10111929B1 (en) 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
CN113072617B (zh) * 2021-03-30 2023-08-08 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用
CN113045625B (zh) * 2021-03-30 2023-11-07 成都诺和晟泰生物科技有限公司 作为生长激素促分泌素受体激动剂的多肽及其应用
CN114805487B (zh) * 2022-06-07 2024-03-12 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264565A (en) 1991-01-22 1993-11-23 Affymax Technologies, N.V. Nucleic acid encoding the D2 /Ml chimeric receptor
HU224345B1 (hu) 1993-12-23 2005-08-29 Novo Nordisk A/S. Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
CA2180844A1 (fr) 1994-01-13 1995-07-20 W. Clark Still Recepteurs de synthese, leurs bibliotheques et leurs utilisations
CA2201122A1 (fr) 1994-09-27 1996-04-04 Romano Deghenghi Composes polypeptides contenant d-2-alkyltryptophanne pouvant promouvoir la liberation de l'hormone de croissance
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
CA2224434A1 (fr) 1995-06-22 1997-01-09 Novo Nordisk A/S Composes presentant des proprietes de liberation de l'hormone de croissance
IL120424A0 (en) 1995-07-26 1997-07-13 Nps Pharma Inc Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
AU5671099A (en) * 1998-08-14 2000-03-06 The Administrators Of The Tulane Eductional Fund Compounds having growth hormone releasing activity
WO2001007475A1 (fr) 1999-07-23 2001-02-01 Kenji Kangawa Nouveaux peptides
MXPA03000738A (es) 2000-07-24 2003-06-04 Ardana Bioscience Ltd Antagonistas de grelina.
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
WO2006045314A2 (fr) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Utilisation d'un secretagogue de l'hormone de croissance en vue d'accroitre ou de maintenir la masse maigre et/ou pour le traitement de la maladie pulmonaire obstructive chronique
CN103251933A (zh) * 2005-09-29 2013-08-21 益普生制药股份有限公司 用于刺激胃肠运动性的组合物和方法
WO2007106385A2 (fr) * 2006-03-10 2007-09-20 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Utilisation d'un agoniste de la ghréline pour améliorer les effets cataboliques d'un traitement aux glucocorticoïdes
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue

Also Published As

Publication number Publication date
TW200408402A (en) 2004-06-01
CN1674927A (zh) 2005-09-28
EP1542716A4 (fr) 2006-05-10
CA2494300C (fr) 2011-02-08
JP4365319B2 (ja) 2009-11-18
AU2003259062A1 (en) 2004-02-25
MXPA05000974A (es) 2005-05-16
WO2004014415A1 (fr) 2004-02-19
BRPI0313273B8 (pt) 2021-05-25
DK1542716T3 (da) 2010-02-01
JP2005535707A (ja) 2005-11-24
EP2130548A2 (fr) 2009-12-09
US7456253B2 (en) 2008-11-25
BR122016015852B1 (pt) 2018-06-19
AR040965A1 (es) 2005-04-27
AR062801A2 (es) 2008-12-10
NO20050205L (no) 2005-03-04
PL212138B1 (pl) 2012-08-31
US20050148515A1 (en) 2005-07-07
PL373605A1 (en) 2005-09-05
EP2130548A3 (fr) 2009-12-23
BR122016015852B8 (pt) 2021-07-27
CA2494300A1 (fr) 2004-02-19
RU2005106236A (ru) 2006-01-20
BRPI0313273B1 (pt) 2019-02-12
US20130123170A1 (en) 2013-05-16
JP5025668B2 (ja) 2012-09-12
RU2007145026A (ru) 2009-06-10
US9409948B2 (en) 2016-08-09
TWI331922B (en) 2010-10-21
RU2323941C2 (ru) 2008-05-10
US8859729B2 (en) 2014-10-14
US8377865B2 (en) 2013-02-19
CN101108875A (zh) 2008-01-23
EP1542716B1 (fr) 2009-11-04
US20150031615A1 (en) 2015-01-29
US20200017548A1 (en) 2020-01-16
CN102850436A (zh) 2013-01-02
ATE447411T1 (de) 2009-11-15
IL165998A (en) 2015-09-24
CZ20041254A3 (cs) 2005-04-13
US20170362275A1 (en) 2017-12-21
AU2003259062B2 (en) 2007-06-21
EP1542716A1 (fr) 2005-06-22
KR100967572B1 (ko) 2010-07-05
JP2009149659A (ja) 2009-07-09
SG177006A1 (en) 2012-01-30
CN102850436B (zh) 2017-06-16
BRPI0313273A8 (pt) 2016-04-19
ES2334223T3 (es) 2010-03-08
BR0313273A (pt) 2005-07-05
KR20050034716A (ko) 2005-04-14
DE60329923D1 (de) 2009-12-17
US20160311855A1 (en) 2016-10-27
IL165998A0 (en) 2006-01-15
US20080242619A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
HK1072908A1 (en) Growth hormone releasing peptides
AU2002342653A8 (en) Modified growth hormone
HUP0402496A3 (en) Growth hormone fusion protein
AU2003290563A8 (en) Leptin-related peptides
HUP0203243A2 (en) Kits containing growth hormone secretagogue
EP1559649A4 (fr) Satellite artificiel
GB0324265D0 (en) Peptide
EP1573046A4 (fr) Hormone de liberation de l'hormone de croissance ti resistant aux proteases
AU2003297317A8 (en) Defensin-inducing peptides from fusobacterium
AU2003228863A8 (en) Immunogenic peptides
HUP0402334A3 (en) Modified human growth hormone
GB0218977D0 (en) Polypeptide
GB0203552D0 (en) Peptide growth factor
GB0106565D0 (en) Growth hormone treatment
GB0202275D0 (en) Peptide
GB0223193D0 (en) Polypeptide
AU2003302330A8 (en) Antimicrobial peptides
GB0209334D0 (en) Protein stabilisation
AU2002364314A8 (en) Growth hormone agonist peptides and their uses
AU2003239777A8 (en) Multimerised growth hormone fusion proteins
GB0205206D0 (en) Synthetic peptides
GB0210746D0 (en) Peptide
GB0208119D0 (en) Growth Hormone Secretagogues
GB0208120D0 (en) Growth hormone secretagogues
GB0208116D0 (en) Growth hormone secretagogues

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210805